Search results
Showing 241 to 255 of 272 results for carcinoma
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
This guidance has been updated and replaced by NICE technology appraisal guidance 849.
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
This guidance has been updated and replaced by NICE technology appraisal guidance 432.
In development Reference number: GID-TA11008 Expected publication date: TBC
Discontinued Reference number: GID-TA10202
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
In development Reference number: GID-TA11831 Expected publication date: TBC
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
In development Reference number: GID-TA11556 Expected publication date: TBC
In development Reference number: GID-TA11751 Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.